120086-34-2

Usage

Uses

Used in Medicinal Chemistry:
1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline is used as a synthetic intermediate for the development of new pharmaceutical compounds. Its structural attributes, including the tetrahydroisoquinoline core and the fluorophenyl substituent, may contribute to the creation of molecules with specific biological activities, such as modulating signaling pathways or interacting with particular receptors.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline is utilized as a key component in the design and synthesis of drugs targeting various therapeutic areas. The presence of the fluorine atom can influence the pharmacokinetics and pharmacodynamics of the resulting compounds, potentially improving their efficacy, selectivity, and safety profiles.
Used in Materials Science:
1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline may also find applications in materials science, where its unique structure could be leveraged to develop new materials with specific properties. For instance, it could be used in the creation of organic materials with tailored electronic, optical, or mechanical characteristics for use in various high-tech applications.
Further research is essential to fully explore the chemical properties and potential applications of 1-(4-Fluorophenyl)-1,2,3,4-tetrahydroisoquinoline, ensuring that its use in these industries is optimized and its benefits are fully realized.

InChI:InChI=1/C15H14FN/c16-13-7-5-12(6-8-13)15-14-4-2-1-3-11(14)9-10-17-15/h1-8,15,17H,9-10H2

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 456-22-4 4-Fluorobenzoic acid 
• 64-04-0 phenethylamine 
• 33799-96-1 N-(2-phenylethyl)-4-fluorobenzamide 
• 344261-84-3 1-(4-fluorophenyl)-3,4-dihydroisoquinoline 

Relevant academic research and scientific papers

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds of formula (I) that modulate progranulin and methods of using the compounds in progranulin- associated disorders, such as Frontotemperal lobe dementia (FTLD).

Discovery of quinuclidine modulators of cellular progranulin

Phenotypic screening of an annotated small molecule library identified the quinuclidine tetrahydroisoquinoline solifenacin (1) as a robust enhancer of progranulin secretion with single digit micromolar potency in a murine microglial (BV-2) cell line. Subsequent SAR development led to the identification of 29 with a 38-fold decrease in muscarinic receptor antagonist activity and a 10-fold improvement in BV-2 potency.

Diprotonative stabilization of ring-opened carbocationic intermediates: conversion of tetrahydroisoquinoline to triarylmethanes

Superacid-promoted conversion of tetrahydroisoquinolines to triarylmethanes via tandem reactions of C-N bond scission, Friedel-Crafts alkylation, C-O bond scission, and electrophilic aromatic amidation was developed. Dication formation was important for stabilizing the ring-opened carbocationic intermediate, which is a new role for diprotonation in reaction mechanisms. This journal is

PROGRANULIN MODULATORS AND METHODS OF USING THE SAME

Provided herein are compounds that modulate progranulin and methods of using the compounds in progranulin-associated disorders, such as Frontotemporal dementia (FTD).

Phencyclidine-like Effects of Tetrahydroisoquinolines and Related Compounds

A series of 1,2,3,4-tetrahydroisoquinolines, tetrahydrothienopyridines, and related compounds were evaluated for their ability to inhibit binding of -1--N-allylnormetazocine to phencyclidine (PCP) and ? receptors, respectively.A representative series of compounds was evaluated in behavioral assays to determine the ability of the compounds to induce PCP-like stereotyped behavior and ataxia.All of the compounds caused stereotyped behavior and ataxia, indicating their agonist actions at the PCP site.